Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 321

Sort by

Sort Order Select

Journal Articles

ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic

Joachim Yahalom, Bouthaina Shbib Dabaja, Umberto Ricardi, Andrea Ng, N. George Mikhaeel, Ivan R. Vogelius, Tim Illidge, Shunan Qi, Andrew Wirth, Lena Specht

Blood (2020) 135 (21): 1829–1832.

https://doi.org/10.1182/blood.2020006028

Published: 2020

Includes: Supplemental data

Journal Articles

Diagnosing HIT: the need for speed

Adam Cuker, Douglas B. Cines

Blood (2020) 135 (14): 1082–1083.

https://doi.org/10.1182/blood.2019004676

Published: 2020

Journal Articles

Treatment of unusual thrombotic manifestations

Maria Abbattista, Marco Capecchi, Ida Martinelli

Blood (2020) 135 (5): 326–334.

https://doi.org/10.1182/blood.2019000918

Published: 2020

Journal Articles

Barriers to the Use of Endari™ in an Urban Adult Sickle Cell Center

Ugochi Olivia Ogu, MD, Merin Thomas, NP, Florence Chan, PharmD, Gracy Sebastian, NP, Caterina P. Minniti, MD

Blood (2019) 134 (Supplement_1): 2287.

https://doi.org/10.1182/blood-2019-126666

Published: 2019

Journal Articles

Updates in Clinical Data on FDA Fast Track Drugs for Relapsed Refractory Multiple Myeloma: A Systematic Review of Literature

Muhammad Abdullah Yousaf, MBBS, MD, Muhaddis Ejaz Ahmad, MD, Maaz Ahmed Yusufi, MD, Asim Tameez ud din, MD, Muhammad Qudrat Ullah, MD, Muhammad Yasir Anwar, MD, Abdul Rafae, MD, Mustafa Nadeem Malik, MD, Zunairah Shah, MBBS, Ahmed Ibrahim, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5579.

https://doi.org/10.1182/blood-2019-123296

Published: 2019

Journal Articles

Risk Adapted Antifungal Strategy in Allogeneic Stem Cell Transplantation. Should We Change the Current Guidelines?

Lucrecia Yanez San Segundo, MD PhD, Noemi Fernandez Escalada, MD, Arancha Bermúdez, MD, Guillermo Martín Sánchez, MD, Sara García Avila, MD, Mónica López Duarte, MD, Mercedes Colorado, MD, Iñigo Romon, MD PhD, Carlos Richard, MD, Enrique M. Ocio, MD PhD

Blood (2019) 134 (Supplement_1): 5655.

https://doi.org/10.1182/blood-2019-130731

Published: 2019

Journal Articles

Which One, Generic Vs Original Glivec Is More Effective in Patients with Chronic Myeloid Leukemia?

Ekin Kircali, Guldane Cengiz Seval, Sinem Civriz Bozdag, MD, Selami Kocak Toprak, MD, Meltem Kurt Yuksel, MD, Onder Arslan, Muhit Özcan, Taner Demirer, MD, Gunhan Gurman, MD, Osman Ilhan, Hamdi Akan, MD, Meral Beksac, MD, Pervin Topcuoglu, MD

Blood (2019) 134 (Supplement_1): 4156.

https://doi.org/10.1182/blood-2019-127622

Published: 2019

Journal Articles

Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies

Jennifer Woyach, MD, Deborah M. Stephens, DO, Ian W. Flinn, MD PhD, Seema A. Bhat, MD, Ronald E. Savage, Feng Chai, MD, Sudharshan Eathiraj, PhD, Lindsey Granlund, Lyndsey A. Szuszkiewicz, Brian Schwartz, MD, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 4298.

https://doi.org/10.1182/blood-2019-127260

Published: 2019

Journal Articles

Development and Performance of Risk Stratification Models for AML Patients Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report

Blood (2019) 134 (Supplement_1): 2691.

https://doi.org/10.1182/blood-2019-124529

Published: 2019

Journal Articles

NUDT15 Variants Confer High Incidence of Secondary Malignancies of ALL in Children

Blood (2019) 134 (Supplement_1): 2751.

https://doi.org/10.1182/blood-2019-125713

Published: 2019

Journal Articles

ASXL1 / SRSF2 Co-Mutated Acute Myeloid Leukemia (AML): A Rare but Distinct Subpopulation with Dismal Outcomes

Daniel R. Richardson, MD MA, David M Swoboda, MD, Anastasia Ivanova, PhD, Steven M Johnson, MD, Jonathan Galeotti, MD MS, Sonia Esparza, MD, Onyee Chan, MD, Matthew C Foster, MD, Catherine C. Coombs, MD, Nathan D Montgomery, MD, David A Sallman, MD, Joshua F Zeidner, MD

Blood (2019) 134 (Supplement_1): 2598.

https://doi.org/10.1182/blood-2019-122929

Published: 2019

Journal Articles

Outcomes of Patients with Suboptimal /Warning Response to Tyrosine Kinase Inhibitors: A Comparison of the 2009 and 2013 Guidelines of the European Leukemianet

Hycienth O Ahaneku, MD MPH, PhD, Hagop M. Kantarjian, MD, Graciela M. Nogueras González, MPH, Gautam M. Borthakur, MD, Srdan Verstovsek, MD PhD, Tapan M. Kadia, MD, Naveen Pemmaraju, MD, Guillermo Garcia-Manero, MD, Marina Y Konopleva, MD PhD, Courtney D. DiNardo, MDMSc, Kiran Naqvi, MDMPH, Koji Sasaki, MD, Ghayas C. Issa, MD, Elias Jabbour, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 2930.

https://doi.org/10.1182/blood-2019-129108

Published: 2019

Journal Articles

Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration to Maximize Response and Survival Benefit. Survival Benefit Not Restricted to Patients with Objective Response

Karen W.L. Yee, MD, Gail J. Roboz, MD, Casey L. O'Connell, MD, Elizabeth A. Griffiths, MD, Raoul Tibes, MD PhD, Katherine J. Walsh, MD, Wendy Stock, MD, Guillermo Garcia-Manero, MD, Michael R. Savona, MD, Farhad Ravandi, MD, Naval G. Daver, MD, Elias Jabbour, MD, Todd L. Rosenblat, MD MS, Jean-Pierre Issa, MD, Xiang Yao Su, PhD, Mohammad Azab, MD, Hagop M. Kantarjian, MD

Blood (2019) 134 (Supplement_1): 3846.

https://doi.org/10.1182/blood-2019-129845

Published: 2019

Journal Articles

Allogeneic Stem Cell Transplantation (alloHSCT) for Chronic Lymphocytic Leukemia (CLL) in the Era of Novel Agents

Lindsey E. Roeker, MD, Jennifer R. Brown, MD PhD, Peter Dreger, Oscar B Lahoud, MD, Toby A. Eyre, MBBChir, MRCP, Danielle M. Brander, MD, Alan Skarbnik, MD, Catherine C. Coombs, MD, Haesook T. Kim, PhD, Steven T Manchini, BS, Timothy J Voorhees, MD, Kim H. Orchard, MBBS,PhDFRCP,FRCPath, Harriet S Walter, Arvind K. Arumainathan, FRCPath, MBBS, MRCP,, Andrea Sitlinger, MD, Craig S. Sauter, MD, Sergio A Giralt, MD, Miguel-Angel Perales, MD, Anthony R. Mato, MDMSCE

Blood (2019) 134 (Supplement_1): 3321.

https://doi.org/10.1182/blood-2019-124140

Published: 2019

Journal Articles

Genome Data Allow in silico Pharmacogenetic Studies Using the Genetic Makeup of Both the Individual Patient As Well As the Disease

Manja Meggendorfer, PhD, Wencke Walter, PhD, Stephan Hutter, PhD, Constance Baer, PhD, Claudia Haferlach, MD, Wolfgang Kern, MD, Torsten Haferlach, MD

Blood (2019) 134 (Supplement_1): 3360.

https://doi.org/10.1182/blood-2019-126580

Published: 2019

Journal Articles

Specific Guidelines Including Multidisciplinary Approach Is Critical of Management of Langerhans Cell Histiocytosis in Adults

Lorenzo Rizzo, Michelina Santopietro, MD, Gianluca Sfaciotti, MD, Marco Brunori, MD, Luisa Cardarelli, MD, Giovanna Palumbo, MD, Daniela De Benedittis, MD, Martina Di Palma, Maria Luisa Moleti, MD, Anna Maria Testi, MD, Tiziana Di Pippo, Fiorina Giona, MD

Blood (2019) 134 (Supplement_1): 1041.

https://doi.org/10.1182/blood-2019-129707

Published: 2019

Journal Articles

Feasibility of Peripheral Blood Stem Cell Collection from Heterozygoussickle Cell Trait Donors

Juergen Foell, MD, Morad Morez, Anja Troeger, MD, Katharina Kleinschmidt, MD PhD, Beatrix Pfirstinger, Andreas Brosig, MD PhD, Ralph Burkhardt, MD PhD, Selim Corbacioglu, MD, Norbert Ahrens

Blood (2019) 134 (Supplement_1): 1171.

https://doi.org/10.1182/blood-2019-131984

Published: 2019

Journal Articles

Do Guidelines Influence Diagnostic and Therapeutic Practice in Immune Thrombocytopenia? Results of a Multicenter Retrospective Study

Blood (2019) 134 (Supplement_1): 1088.

https://doi.org/10.1182/blood-2019-125557

Published: 2019

Journal Articles

Persistence of PNH Clones over Time: Insights from the Mid-Term Analysis of the French Nation-Wide Multicenter Prospective Observational Study

Magali Le Garff-Tavernier, Agathe Pruvot Debliquis, PharmD, Thomas Boyer, MD, Jean-Philippe Vial, MD, Véronique Harrivel, MD, Anne-Catherine Lhoumeau, PhD PharmD, Marie-Christine Jacob, MD, Gerard Socie, MD PhD, Regis Peffault de Latour, MD PhD, Bernard Drenou, MD PhD, Orianne Wagner Ballon, MD PhD

Blood (2019) 134 (Supplement_1): 1218.

https://doi.org/10.1182/blood-2019-123415

Published: 2019

Journal Articles

A Novel Automated Image Analysis System Using Deep Convolutional Neural Networks to Diagnose MDS

Konobu Kimura, Yoko Tabe, MD PhD, Tomohiko Ai, MD PhD, Akihiko Matsuzaki, Kumiko Nishibe, Miki Ebihara, Kimiko Kaniyu, Ikki Takehara, PhD, Kinya Uchihashi, PhD, Akimichi Ohsaka, MD PhD

Blood (2019) 134 (Supplement_1): 4670.

https://doi.org/10.1182/blood-2019-129524

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic

Diagnosing HIT: the need for speed

Treatment of unusual thrombotic manifestations

Barriers to the Use of Endari™ in an Urban Adult Sickle Cell Center

Updates in Clinical Data on FDA Fast Track Drugs for Relapsed Refractory Multiple Myeloma: A Systematic Review of Literature

Risk Adapted Antifungal Strategy in Allogeneic Stem Cell Transplantation. Should We Change the Current Guidelines?

Which One, Generic Vs Original Glivec Is More Effective in Patients with Chronic Myeloid Leukemia?

Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies

Development and Performance of Risk Stratification Models for AML Patients Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report

NUDT15 Variants Confer High Incidence of Secondary Malignancies of ALL in Children

ASXL1 / SRSF2 Co-Mutated Acute Myeloid Leukemia (AML): A Rare but Distinct Subpopulation with Dismal Outcomes

Outcomes of Patients with Suboptimal /Warning Response to Tyrosine Kinase Inhibitors: A Comparison of the 2009 and 2013 Guidelines of the European Leukemianet

Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration to Maximize Response and Survival Benefit. Survival Benefit Not Restricted to Patients with Objective Response

Allogeneic Stem Cell Transplantation (alloHSCT) for Chronic Lymphocytic Leukemia (CLL) in the Era of Novel Agents

Genome Data Allow in silico Pharmacogenetic Studies Using the Genetic Makeup of Both the Individual Patient As Well As the Disease

Specific Guidelines Including Multidisciplinary Approach Is Critical of Management of Langerhans Cell Histiocytosis in Adults

Feasibility of Peripheral Blood Stem Cell Collection from Heterozygoussickle Cell Trait Donors

Do Guidelines Influence Diagnostic and Therapeutic Practice in Immune Thrombocytopenia? Results of a Multicenter Retrospective Study

Persistence of PNH Clones over Time: Insights from the Mid-Term Analysis of the French Nation-Wide Multicenter Prospective Observational Study

A Novel Automated Image Analysis System Using Deep Convolutional Neural Networks to Diagnose MDS

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only